FDA Provides Accelerated Approval of Talvey for Multiple Myeloma

TUESDAY, Aug. 15, 2023 (HealthDay News) -- The U.S. Food and Drug Administration has approved Talvey (talquetamab-tvgs) for patients with relapsed or refractory multiple myeloma.
The accelerated approval is for individuals who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. Talvey is a bispecific antibody targeting CD3 on T cells and G protein-coupled receptor class C group 5 member D, expressed on the surface of multiple myeloma cells.
Findings from the phase 2 MonumenTAL-1 study showed both a positive response rate and durability of response. At a biweekly dose of 0.8 mg/kg, 73.6 percent of patients achieved an overall response rate. Over a median of six months from first response among responders, 58 percent of patients achieved a very good partial response or better, including 33 percent of patients achieving a complete response or better. For a weekly dose of 0.4 mg/kg, 73.0 percent of patients achieved an overall response rate, and over a median of nearly 14 months from first response among responders, 57 percent of patients achieved a very good partial response or better, including 35 percent of patients achieving a complete response or better. In the 0.8 mg/kg biweekly dose group, an estimated 85 percent of responders maintained response for at least nine months.
The most common nonhematologic adverse effects were oral toxicities (80 percent of patients), weight loss (62 percent), and serious infections (16 percent).
Approval of Talvey was granted to Janssen.
Related Posts
Use of Medications for Opioid Use Disorder Low
WEDNESDAY, March 30, 2022 (HealthDay News) -- Only one in four people who could...
La OMS declara el fin de la emergencia mundial por la COVID
VIERNES, 5 de mayo de 2023 (HealthDay News) -- Más de tres años después de que...
DDW: Endoscopic Procedure May Eliminate Insulin Use in T2DM
TUESDAY, May 2, 2023 (HealthDay News) -- Recellularization via electroporation...
Successful Intubations Up With Nasal High-Flow Therapy in Neonates
WEDNESDAY, April 27, 2022 (HealthDay News) -- For neonates undergoing...